- COMMENT
ENABLE: an engine for European antibacterial drug discovery and development
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 20, 407-408 (2021)
doi: https://doi.org/10.1038/d41573-021-00074-y
Acknowledgements
The authors thank all colleagues and partners involved in ENABLE (Supplementary Table 2), and gratefully acknowledge PMC members and platform leads for providing valuable insights. The authors wish to thank members of the Consortium Management Office, C. Nilsson, E. Bacqué, N. Pearson, R. Neal, F. Deroose, A. Lobell, N. Murillo, L. Löwenau and C. Robijns, for their contributions as well as critical reading of the manuscript. R. Stavenger is acknowledged for his tremendous efforts in helping to set up ENABLE and ensuring its smooth running in the early years. The authors have received support from the IMI Joint Undertaking under grant agreement no. 115583, resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme and EFPIA companies’ in-kind contributions.
Disclaimer
The views expressed in this article are the views of the authors and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
Supplementary Information
Competing Interests
The authors declare no competing interests.